Amerise Biosciences Limited (formerly known as **Amradeep Industries Limited**) is an Indian listed entity currently navigating a transitional phase characterized by operational inactivity, significant financial restructuring, and a strategic pivot toward becoming a financial intermediary and investment vehicle. While the company reported **zero revenue from operations** in the most recent fiscal cycle, it is aggressively seeking shareholder authorization to mobilize capital and expand its borrowing and investment capacities. --- ### **Strategic Pivot: Capital Mobilization and Financial Intermediation** The company is executing a strategy to transform its balance sheet into a platform for strategic investments and corporate financing. To facilitate this, the Board has sought and obtained authorizations to significantly exceed standard statutory limits for financial exposure. **Financial Authorization Limits (2024-2025)** | Category | Limit | Strategic Intent | | :--- | :--- | :--- | | **Borrowing Limit** | **Rs. 100.00 Crores** | Authorized under **Section 180(1)(c)** to exceed the aggregate of paid-up capital and free reserves to fund future growth. | | **Investment & Loan Limit** | **Rs. 100.00 Crores** | Authorized to deploy capital into loans, guarantees, or securities of other bodies corporate. | | **Section 186 Compliance** | **Exceeding 60% Threshold** | Authorization to bypass the standard limit (60% of paid-up capital/reserves or 100% of reserves) for aggressive deployment. | This framework positions Amerise Biosciences as a potential **strategic investor and financier**, allowing the Board to acquire securities in one or more tranches and provide inter-corporate support to third parties. --- ### **Current Financial Standing and Asset Portfolio** The company’s current financial state reflects a period of "sluggish market conditions" and a total cessation of active business turnover. The focus remains on managing a legacy portfolio of financial assets while absorbing fixed administrative costs. **Key Financial Metrics (As of March 31, 2024)** * **Revenue from Operations:** **Nil** * **Net Loss:** **Rs. 14,61,331** * **Paid-up Share Capital:** **Rs. 6,60,69,000** (comprising **6,60,69,000** equity shares at **Rs. 1** face value) * **Dividend/Reserve Transfer:** **Nil** (due to accumulated losses) **Asset and Liability Composition** Despite the lack of operational revenue, the company maintains a baseline of financial assets: * **Loans Outstanding:** **Rs. 310.17 Lacs** * **Investments:** **Rs. 226.50 Lacs** * **Guarantees Given:** **Nil** --- ### **Governance Framework and Leadership Continuity** The company operates under a lean management structure designed to maintain statutory existence and provide oversight for its proposed financial expansion. Governance is managed through the **Nomination and Remuneration Committee (NRC)** and adheres to the **Companies Act, 2013**. **Board Composition & Key Personnel** | Role | Personnel | Status/Tenure | | :--- | :--- | :--- | | **Chief Financial Officer (CFO)** | **Mr. Dineshkumar Rathod** | Active; Director subject to retirement by rotation. | | **Company Secretary** | **Ms. Minal Lakhlani** | Active; Responsible for statutory and secretarial functions. | | **Independent Director** | **Ms. Manisha Patel** | Re-appointed for a **5-year term** (until **September 2028**). | | **Independent Director** | **Additional Appointees** | New terms extending up to **September 2029** to ensure board diversity. | The leadership team is currently focused on **stringent cost-reduction measures** to preserve the company’s legal standing during its non-operational phase. --- ### **Critical Risk Factors and Regulatory Challenges** Investors should note that Amerise Biosciences faces significant existential risks. The company is currently **non-operational**, and its future is entirely dependent on the successful commencement of new business activities, for which no specific sector has yet been identified. **Operational and Liquidity Risks** * **Working Capital Scarcity:** There is a critical lack of funds required to initiate new business operations. * **Operational Dependency:** Future viability relies solely on the transition from a dormant state to an active one. * **Fixed Cost Pressure:** In the absence of turnover, fixed expenses continue to erode the capital base, leading to consistent net losses. **Compliance and Administrative Lapses** The company has faced several regulatory hurdles and audit qualifications: * **SEBI (LODR) Non-compliance:** Failure to publish statutory notices (Board Meetings, AGM) and quarterly financial results in newspapers. * **Internal Audit Gaps:** Failure to appoint an **Internal Auditor** as mandated by **Section 138** of the Companies Act, 2013. * **Transparency Issues:** The company opted **not to provide a Corporate Governance Report** under **Regulation 34 of SEBI (LODR)**. * **Audit Limitations:** Secretarial audits have noted a reliance on external statutory audits for tax law compliance, rather than independent internal reviews. ### **Summary for Investors** Amerise Biosciences Limited is a "shell-plus" entity—it possesses a listed platform and a mandate for significant capital mobilization (**Rs. 100 Crores**), but currently lacks an active business engine. The investment thesis rests on the management's ability to utilize its newly authorized borrowing and investment powers to acquire productive assets or pivot into a new industry. Until such activities commence, the company remains a high-risk vehicle characterized by liquidity constraints and regulatory compliance challenges.